Peptide Bureau news https://peptidebureau.com/peptide-news.html Fact-checked peptide regulation and market news. en The FDA's Peptide 'Interim Access Policy' Is at the White House: What the Filing Shows and Who Has Asked to Meet on It https://peptidebureau.com/peptide-interim-access-policy-white-house-review.html https://peptidebureau.com/peptide-interim-access-policy-white-house-review.html Tue, 20 Oct 2026 10:23:00 +0100 The FDA sent a peptide compounding policy to the White House on 14 October. What the filing shows, who has asked to meet on it, and what is still unknown. Black-Market Retatrutide: Two Death Reports to the FDA, Rising Poison Center Calls and Five More Lilly Lawsuits https://peptidebureau.com/black-market-retatrutide-deaths-lawsuits-october-2026.html https://peptidebureau.com/black-market-retatrutide-deaths-lawsuits-october-2026.html Wed, 14 Oct 2026 00:55:00 +0100 Two deaths reported to the FDA after bootleg retatrutide, 862 poison center exposures in a quarter, five new Lilly suits. What is verified and what is not. Are Peptides Legal Now? The Reported 'Temporary Sale' Plan, Checked Against the Record https://peptidebureau.com/peptide-temporary-sale-plan-fact-check.html https://peptidebureau.com/peptide-temporary-sale-plan-fact-check.html Wed, 14 Oct 2026 00:54:00 +0100 No FDA order exists yet. What the Washington Post reported on 7 October, what it would cover, why research-use vendors are not part of it, what to watch.